HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ivan Votruba Selected Research

Lymphoma (Lymphomas)

7/2011Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG.
7/2010Role of caspases and CD95/Fas in the apoptotic effects of a nucleotide analog PMEG in CCRF-CEM cells.
4/2009In vivo modulation of angiogenic gene expression by acyclic nucleoside phosphonates PMEDAP and PMEG.
2/2008Syntheses of N3-substituted thymine acyclic nucleoside phosphonates and a comparison of their inhibitory effect towards thymidine phosphorylase.
1/2007Syntheses of pyrimidine acyclic nucleoside phosphonates as potent inhibitors of thymidine phosphorylase (PD-ECGF) from SD-lymphoma.
5/2005Inhibition of thymidine phosphorylase (PD-ECGF) from SD-lymphoma by phosphonomethoxyalkyl thymines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ivan Votruba Research Topics

Disease

6Lymphoma (Lymphomas)
07/2011 - 05/2005
4Neoplasms (Cancer)
08/2013 - 11/2007
3Leukemia
02/2012 - 02/2008
3T-Cell Lymphoma (Lymphoma, T Cell)
02/2010 - 05/2005
1Hematologic Neoplasms (Hematological Malignancy)
05/2013
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
06/2011
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
09/2010
1Adenoviridae Infections (Adenovirus Infections)
10/2008
1Carcinoma (Carcinomatosis)
10/2008
1Non-Hodgkin Lymphoma (Lymphosarcoma)
10/2008
1Chromosome Aberrations (Chromosome Abnormalities)
11/2003
1Polydactyly (Polydactylism)
11/2003

Drug/Important Bio-Agent (IBA)

8NucleosidesIBA
08/2013 - 11/2003
79-((2-phosphonylmethoxy)ethyl)guanineIBA
05/2013 - 11/2003
5Organophosphonates (Phosphonates)IBA
09/2010 - 11/2003
5Thymidine PhosphorylaseIBA
02/2010 - 05/2005
3NucleotidesIBA
05/2013 - 07/2010
3ProdrugsIBA
05/2013 - 07/2010
39- (2- phosphonylmethoxyethyl)- 2,6- diaminopurineIBA
09/2010 - 11/2003
3ThymineIBA
02/2010 - 05/2005
2Messenger RNA (mRNA)IBA
02/2012 - 02/2008
2Cytostatic AgentsIBA
01/2011 - 01/2010
1Proteins (Proteins, Gene)FDA Link
02/2012
1MethyltransferasesIBA
06/2011
1Telomerase (Telomerase Reverse Transcriptase)IBA
09/2010
1GuanineIBA
07/2010
1SugarsIBA
02/2010
1Phosphorous AcidsIBA
02/2010
1Clofarabine (Clolar)FDA Link
01/2010
1Antimitotic AgentsIBA
04/2009
1N- (5- ((2- (2- (hexadecyloxy)ethoxy)- 2- oxido- 1,4,2- dioxaphosphinan- 5- yl)methyl)- 4- oxo- 4,5- dihydro- 1,3,5- triazin- 2- yl)docosanamideIBA
10/2008
1DCMP Deaminase (Deoxycytidylate Deaminase)IBA
10/2008
1Diphosphates (Pyrophosphates)IBA
10/2008
1DecitabineFDA Link
02/2008
1pyrimidineIBA
01/2007
1EnzymesIBA
05/2005
19- (2- (phosphonomethoxy)ethyl)- N(6)- allyl- 2,6- diaminopurineIBA
11/2003
19- (2- (phosphonomethoxy)ethyl)- N(6)- dimethyl- 2,6- diaminopurineIBA
11/2003
19- (2- (phosphonomethoxy)ethyl)- N(6)- (2- dimethylaminoethyl)- 2,6- diaminopurineIBA
11/2003

Therapy/Procedure

2Therapeutics
06/2011 - 11/2007
1Drug Therapy (Chemotherapy)
07/2010
1Aftercare (After-Treatment)
11/2003